Exciting update for North America customers

We are delighted to announce the launch of a brand-new branch office dedicated to serving the needs of RGCC Network doctors in North America.

Find out more
Download our app Order a test
News

New oral inhibitor improves pancreatic cancer treatment

Scientists have developed a new oral DPP inhibitor that, when used in combination with targeted immunotherapy, has shown promise at treating pancreatic cancer. In trials, the combination therapy proved to be successful at increasing the number of cancer-killing cells around a tumour, reducing its growth and, in some cases, eliminating cancer altogether. The authors believe […]

Read more
News

Chemotherapy drugs open door to cancer cells

Chemotherapy drugs could enhance the spread of cancer beyond a primary tumour site, scientists have established. In tests, researchers found that mice injected with cyclophosphamide, a popular chemotherapy drug, enabled breast cancer cells to squeeze through the blood vessel linings in the lungs and stick to cell walls. While chemotherapy remains an effective treatment for […]

Read more
News

How cancer cells evade the immune system

Mutations in cancer-suppressing genes that block cell growth may explain why some cancers evade the body’s immune system, scientists have established. A US team has identified 100 “mutated tumor suppressor genes” that affect the body’s ability to spot and destroy cancer cells in mice. While at an early stage, identifying genetic mutations could lead to […]

Read more
News

Molecular boost for cancer immunotherapies

Scientists have identified a new synthetic molecular code that could improve a patient’s response to an effective cancer treatment, known as PD-1 blockade immunotherapy. The team from Kyoto University have created a new molecular code that ensures a supply of energy to cancer-killing T-cells. The molecular code is highly effective at targeting cancer cells when […]

Read more
News

Researchers identify a key enzyme in tumours

Researchers have identified a key enzyme that cancerous tumours rely on to grow and spread within the body. Described as cancer’s “Achilles Heel”, scientists believe that targeting this enzyme stops tumour cells from growing and spreading. The findings could accelerate the development of new treatments for solid-tumour cancers. Solid cancerous tumours rely on an available […]

Read more
News

ctDNA accurate at diagnosing rectal cancer relapse

Combining circulating tumour DNA (ctDNA) with magnetic resonance imaging (MRI) can more accurately predict the likelihood of locally advanced rectal cancer (LARC) returning after treatment, Chinese scientists have found. In a new study published in PLOS Medicine, researchers describe how combining the techniques improved diagnosis and could improve treatment and outcomes for patients. In addition, […]

Read more
News

Measuring circulating tumour DNA can improve bladder cancer treatment

The presence of circulating tumour DNA (ctDNA) is a crucial biomarker for patients with bladder cancer (urothelial carcinoma) researchers have found in a new study. Scientists suggest that post-operative screening for ctDNA could improve cancer treatments and patient outcomes. The authors hope the findings could help improve outcomes for bladder cancer and more broadly illustrates […]

Read more
News

Promising new immunotherapy for colorectal cancer patients

Patients with advanced colorectal cancer can benefit from treatment with advanced immunotherapy, known as immune checkpoint inhibitor PD-1/PD-L1, scientists have discovered. The findings provide new hope for colorectal cancer patients and more broadly demonstrate the incredible potential for immunotherapies to extend life and treat all forms of cancer. If chemotherapy fails, patients with microsatellite stable […]

Read more
News

New breast cancer therapy a step closer to clinical trials

An advanced cancer therapy developed by RGCC scientists has been categorised as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA). Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Due to enter clinical trials […]

Read more
News

Activating p53 protein improves cancer-killing potential

Activating protein p53 can boost a patient’s immune response against cancerous tumours, researchers at Sweden’s Karolinska Institutet have discovered. Using a commercially available substance known as ALRN-6924, the team successfully generated an anti-tumour immune response. The finding improves our understanding of the crucial role p53 plays in tumour development. In the future, it could help […]

Read more
News

RGCC scientists develop novel new approach to inhibiting SARS-COV-2 replication

RGCC researchers have developed a new approach to tackling COVID-19 (SARS-CoV-2) that could form the basis of a new treatment option. Laboratory tests have established that the new treatments were effective at inhibiting the spread of the disease. The next stage will see them progress to develop a drug delivery system, a further step before […]

Read more
News

New cancer vaccine effective in 75% of tumours

A new cancer vaccine is 75% effective at eliminating cancerous tumours in mice, say scientists at the University of Konstanz. The combination treatment includes a powerful immunostimulant and a targeted immunotherapy called a cancer checkpoint inhibitor in one dose. Described by the team as a “potent cancer vaccine”, the combination therapy is already being tested […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more